ResearcherUniversity of Campania "Luigi Vanvitelli"Active in the last 2 years
Luca Pompella
Matched on ORCID iD 0000-0002-3072-7919; OpenAlex author ID A5042581102. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 5
- Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16040824↗
- Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Co-author DOI 10.3389/fonc.2021.695627↗
- Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. Co-author DOI 10.3390/ijms21082814↗
- Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Co-author DOI 10.1007/s12032-019-1306-9↗
- Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propen… Co-author DOI 10.1155/2018/2373868↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ferdinando De Vita · 5 shared papers, 2018–2024 · strength 0.56
- Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗
- Paper Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. DOI 10.3389/fonc.2021.695627↗
- Paper Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. DOI 10.3390/ijms21082814↗
- Annalisa Pappalardo · 3 shared papers, 2019–2021 · strength 0.34
- Paper Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. DOI 10.3389/fonc.2021.695627↗
- Paper Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. DOI 10.3390/ijms21082814↗
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Angelica Petrillo · 3 shared papers, 2018–2021 · strength 0.29
- Paper Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. DOI 10.3389/fonc.2021.695627↗
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Michele Orditura · 3 shared papers, 2018–2020 · strength 0.26
- Paper Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. DOI 10.3390/ijms21082814↗
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Fortunato Ciardiello · 2 shared papers, 2019–2024 · strength 0.24
- Chiara Carmen Miceli · 1 shared paper, 2024 · strength 0.16
- Carlo Caputo · 1 shared paper, 2024 · strength 0.16
- Alessandro Ottaiano · 1 shared paper, 2024 · strength 0.16
- Donatella Coradduzza · 1 shared paper, 2024 · strength 0.16
- Michele Caraglia · 1 shared paper, 2024 · strength 0.16
- Gabriella Misso · 1 shared paper, 2024 · strength 0.16
- Teresa Troiani · 1 shared paper, 2018 · strength 0.07
- Jole Ventriglia · 1 shared paper, 2018 · strength 0.07
- Marisol Huerta · 1 shared paper, 2018 · strength 0.07
- Floriana Morgillo · 1 shared paper, 2018 · strength 0.07
- Andrès M.R. Cervantes · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.